AstraZeneca Bets Big On Moderna’s Preclinical Messenger RNA Technology
This article was originally published in The Pink Sheet Daily
Executive Summary
The struggling pharma pays $240 million upfront for an exclusive collaboration to discover, develop and commercialize mRNA drugs in the cardiovascular, metabolic, renal and oncology spaces.
You may also be interested in...
Deal Watch: Anticipated Shire/Baxalta Merger Steals Attention From J.P. Morgan
Industry's leading deal-making stage shows continued focus on immuno-oncology, with activity by Merck, Novartis and AstraZeneca.
Deal Watch: Salix Merges With Italy’s Cosmo In Latest Tax-Inversion Play
A research agreement between AstraZeneca and Germany’s Max Planck Institute and a development pact between Portola and Daiichi Sankyo for an adverse-bleeding therapy highlight the week’s deal-making. In addition, HealthCare Royalty Partners announced a new royalty deal with Supernus and reworked its 2012 loan with Raptor, while GlobeImmune went public on its second IPO attempt.
Doubling Down On Cardiac Regeneration, AstraZeneca Forms Research Alliance With Shanghai SIBS
Going deeper into the cardiac regeneration space, AstraZeneca signed an agreement with SIBS to research coronary artery regeneration.